Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Physical Function with AMG 108 in Rheumatoid Arthritis
2006-003698-29Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMG 108 in rheumatoid arthritis (RA) (2 arms), sponsored by Amgen. Primary endpoints: Long-term safety of AMG 108, Impact of concomitant immunosuppressives on safety and 1 more. Started Aug 2006; status: completed.
02
Drugs
AMG 108
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-003698-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003698-29.